SEARCH

SEARCH BY CITATION

References

  • 1
    World Health Organization. Hepatitis C. Initiative for vaccine research. Available at: http://wwwwhoint/vaccine_research/diseases/viral_cancers/en/index2.html. Accessed January 21, 2009.
  • 2
    Bartenschlager R, Lohmann V. Replication of the hepatitis C virus. Baillieres Best Pract Res Clin Gastroenterol 2000; 14: 241254.
  • 3
    Sentandreu V, Jimenez-Hernandez N, Torres-Puente M, Bracho MA, Valero A, Gosalbes MJ, et al. Evidence of recombination in intrapatient populations of hepatitis C virus. PLoS One 2008; 3: e3239.
  • 4
    Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. HEPATOLOGY 2004; 39: 11471171.
  • 5
    Fried MW, Hadziyannis SJ. Treatment of chronic hepatitis C infection with peginterferons plus ribavirin. Semin Liver Dis 2004; 24(Suppl 2): 4754.
  • 6
    Sarrazin C, Rouzier R, Wagner F, Forestier N, Larrey D, Gupta SK, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007; 132: 12701278.
  • 7
    Forestier N, Reesink HW, Weegink CJ, McNair L, Kieffer TL, Chu HM, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. HEPATOLOGY 2007; 46: 640648.
  • 8
    Reesink HW, Zeuzem S, Weegink CJ, Forestier N, van Vliet A, van de Wetering de Rooij J, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006; 131: 9971002.
  • 9
    Lawitz EJ, Sulkowski MS, Jacobson IM, Faruqui S, Kraft W, Maliakkal B, et al. Safety, tolerability and antiviral activity of MK-7009, a novel inhibitor of the hepatitis C virus NS3/4A protease, in patients with chronic HCV genotype 1 infection [Abstract]. HEPATOLOGY 2008; 48(Suppl): 403A.
  • 10
    Manns MP, Reesink HW, Moreno C, Berg T, Benhamou Y, Horsmans Y, et al. Safety and antiviral activity of TMC435350 in treatment-naive genotype 1 HCV infected patients [Abstract]. HEPATOLOGY 2008; 48(Suppl): 1023A.
  • 11
    Manns MP, Bourliere M, Benhamou Y, Pol S, Bonacini M, Berg, T, et al. Safety and antiviral activity of BI201335, a new HCV NS3 protease inhibitor, in treatment-naive patients with chronic hepatitis C genotype-1 infection given as monotherapy and in combination with peginterferon alfa 2b and ribavirin [Abstract]. HEPATOLOGY 2008; 48(Suppl): 1133A.
  • 12
    Seiwert SD, Andrews SW, Jiang Y, Serebryany V, Tan H, Kossen K, et al. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob Agents Chemother 2008; 52: 44324441.
  • 13
    McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 18271838.
  • 14
    Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 18391850.
  • 15
    Lin C, Gates CA, Rao BG, Brennan DL, Fulghum JR, Luong YP, et al. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem 2005; 280: 3678436791.
  • 16
    Lu L, Pilot-Matias TJ, Stewart KD, Randolph JT, Pithawalla R, He W, et al. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob Agents Chemother 2004; 48: 22602266.
  • 17
    Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 2006; 70: 2838.
  • 18
    Tong X, Bogen S, Chase R, Girijavallabhan V, Guo Z, Njoroge FG, et al. Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antiviral Research 2008; 77: 177185.
  • 19
    Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Müh U, Welker M, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132: 17671777.
  • 20
    Zeuzem S, Sarrazin C, Rouzier R, Tarral A, Brion N, Gupta S, et al. Anti-viral activity of SCH503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype-1 (HCV-1) patients refractory to pegylated interferon (PEG-IFNalfa) [Abstract]. HEPATOLOGY 2005; 42(Suppl 1): 233A.
  • 21
    Welsch C, Domingues FS, Susser S, Antes I, Hartmann C, Mayr G, et al. Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3–4A protease of the hepatitis C virus. Genome Biol 2008; 9: R16.
  • 22
    Taremi SS, Beyer B, Maher M, Yao N, Prosise W, Weber PC, et al. Construction, expression, and characterization of a novel fully activated recombinant single-chain hepatitis C virus protease. Protein Sci 1998; 7: 21432149.
  • 23
    Zhang R, Beyer BM, Durkin J, Ingram R, Njoroge FG, Windsor WT, et al. A continuous spectrophotometric assay for the hepatitis C virus serine protease. Anal Biochem 1999; 270: 268275.
  • 24
    Adiwijaya B, Herrmann E, Khunvichai A, Hare B, Caron P, Garg V, et al. A multi-variant viral kinetic model to estimate the fitness of HCV genotype 1 resistant variants in subjects dosed with telaprevir. In: Reviews in Antiviral Therapy 2008; 1: 2122.
  • 25
    Nowak MA, Bonhoeffer S, Shaw GM, May RM. Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. J Theor Biol 1997; 184: 203217.
  • 26
    Kwo P, Lawitz E, McCone J, Schiff E, Vierling J, Pound D, et al. HCV SPRINT-1 final results: SVR 24 from a phase 2 study of boceprevir plus PegIntron™ (peginterferon alfa-2b)/ribavirin in treatment-naive subjects with genotype-1chronic hepatitis C. J Hepatol 2009; 50(Suppl 1): S4.
  • 27
    Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. HEPATOLOGY 2007; 46: 631639.
  • 28
    Yi M, Tong X, Skelton A, Chase R, Chen T, Prongay A, et al. Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations. J Biol Chem 2006; 281: 82058215.
  • 29
    Zhang EZ, Bartels DJ, Sullivan J, Marcial M, Dorrian J, Tigges A, et al. No compensatory fitness mutations selected in NS3/4A protease cleavage sites during treatment with telaprevir, PEG-IFN-alfa-2a, and ribavirin in phase II studies of treatment naive HCV genotype 1-infected patients [Abstract]. HEPATOLOGY 2008; 48(Suppl): 1138A.